Skip to main content

Table 2 Pooled relative risk of all grade and high grade irAEs for nivolumab vs chemotherapy

From: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

All grade irAEs No. of trials Pooled RR (95% CI) Pooled RR p Value High grade irAEs No. of trials Pooled RR (95% CI) Pooled RR p Value
Total incidence 4 0.728–0.805 0.765 0.000 Total incidence 4 0.149–0.324 0.220 0.000
Discontinuation 1 0.454–1.180 0.732 0.200 Discontinuation 1 0.657–2.254 1.217 0.533
Fatigue 4 0.440–0.627 0.525 0.000 Fatigue 4 0.103–0.418 0.208 0.000
Rash 3 0.647–4.516 1.71 0.279 Rash 3 0.248–5.904 1.210 0.814
Nausea 3 0.221–0.534 0.344 0.000 Nausea 3 0.107–1.447 0.394 0.160
Vomiting 1 0.144–0.422 0.246 0.000 Vomiting 1 0.005–1.611 0.090 0.102
Decreased appetite 4 0.345–0.643 0.471 0.000 Decreased appetite 4 0.071–1.387 0.315 0.127
Constipation 1 0.148–0.633 0.306 0.001 Constipation 1
Diarrhea 3 0.231–1.172 0.52 0.115 Diarrhea 3 0.178–1.424 0.504 0.196
Pneumonia 1 0.729–224.957 12.803 0.081 Pneumonia 1
Arthralgia 1 0.294–1.995 0.766 0.585 Arthralgia 1
Neutrophil count decreased 2 0.018–0.111 0.045 0.000 Neutrophil count decreased 2 0.004–0.149 0.025 0.000
Neutropenia 4 0.005–0.144 0.028 0.000 Neutropenia 4 0.005–0.066 0.019 0.000
Anemia 4 0.075–0.161 0.11 0.000 Anemia 4 0.024–0.228 0.075 0.000
Leukopenia 3 0.028–0.435 0.11 0.002 Leukopenia 3 0.012–0.225 0.053 0.000
WBC count decreased 1 0.059–0.225 0.116 0.000 WBC count decreased 1 0.113–0.253 0.169 0.000